Las Vegas Sands Corp (NYSE:LVS) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. Las Vegas Sands Corp operates fully integrated resorts with casino, hotel, entertainment. The company owns the Venetian Macao, Sands Macao, in Macau, the Marina Bay Sands resort in Singapore, the Venetian and Sands Bethlehem casinos in the United States. Las Vegas Sands Corp has a market cap of $58.76 billion; its shares were traded at around $74.33 with a P/E ratio of 20.99 and P/S ratio of 4.68. The dividend yield of Las Vegas Sands Corp stocks is 3.93%. Las Vegas Sands Corp had annual average EBITDA growth of 15.50% over the past ten years. GuruFocus rated Las Vegas Sands Corp the business predictability rank of 3-star.
For the last quarter Las Vegas Sands Corp reported a revenue of $3.4 billion, compared with the revenue of $3.1 billion during the same period a year ago. For the latest fiscal year the company reported a revenue of $12.9 billion, an increase of 12.9% from last year. For the last five years Las Vegas Sands Corp had an average revenue decline of 0.2% a year.
Top 5 Casino Stocks To Buy For 2019: Sarepta Therapeutics, Inc.(SRPT)
Advisors' Opinion:- [By Joseph Griffin]
Get a free copy of the Zacks research report on Sarepta Therapeutics (SRPT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
- [By Shane Hupp]
Sarepta Therapeutics (NASDAQ:SRPT)’s share price reached a new 52-week high and low on Wednesday after Leerink Swann raised their price target on the stock from $88.00 to $121.00. Leerink Swann currently has an outperform rating on the stock. Sarepta Therapeutics traded as low as $95.67 and last traded at $94.81, with a volume of 42782 shares trading hands. The stock had previously closed at $92.22.
- [By Keith Speights]
But some stocks don't take nearly that long to double. Three stocks in particular�have doubled investors' money -- and more -- in just the last 12 months. Here's why Nektar Therapeutics (NASDAQ:NKTR), CRISPR Therapeutics (NASDAQ:CRSP), and Sarepta Therapeutics (NASDAQ:SRPT) became such huge winners -- and whether or not their impressive momentum can continue.
- [By Max Byerly]
Sarepta Therapeutics (NASDAQ:SRPT) had its target price increased by Morgan Stanley from $87.00 to $91.00 in a report issued on Friday. Morgan Stanley currently has an equal weight rating on the biotechnology company’s stock.
- [By Logan Wallace]
Barclays upgraded shares of Sarepta Therapeutics (NASDAQ:SRPT) from an equal weight rating to an overweight rating in a research report released on Friday morning, MarketBeat.com reports. They currently have $107.00 target price on the biotechnology company’s stock, up from their prior target price of $55.00.
Top 5 Casino Stocks To Buy For 2019: Curis, Inc.(CRIS)
Advisors' Opinion:- [By Logan Wallace]
Curis, Inc. (NASDAQ:CRIS) shares fell 7.3% during trading on Monday . The company traded as low as $0.50 and last traded at $0.51. 1,663,387 shares were traded during trading, a decline of 12% from the average session volume of 1,888,812 shares. The stock had previously closed at $0.55.
- [By Max Byerly]
Get a free copy of the Zacks research report on Curis (CRIS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Top 5 Casino Stocks To Buy For 2019: Tandy Leather Factory, Inc.(TLF)
Advisors' Opinion:- [By Shane Hupp]
Tandy Leather Factory (NASDAQ: TLF) and Vera Bradley (NASDAQ:VRA) are both small-cap retail/wholesale companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.
Top 5 Casino Stocks To Buy For 2019: iAnthus Capital Holdings, Inc. (ITHUF)
Advisors' Opinion:- [By ]
Much of the focus of cannabis investors has been centered on Canada and California. This makes sense given that they are the two largest recreational (or soon to be) cannabis markets in the world. However, one publicly traded company with US-centric cannabis operations has taken a different approach. iAnthus Capital is listed in Canada on the CSE (OTCQB:ITHUF), but is headquartered in New York and incorporated in Delaware. Unlike other Canadian-listed cannabis companies, most of which are aiming to get in on the highly competitive green-rush in California and Canada, iAnthus has set its sights on becoming the dominant player on the U.S. East Coast.
- [By Javier Hasse]
Licensed cannabis production facilities owner and operator iAnthus Capital Holdings Inc (OTC: ITHUF) announced a $50 million investment from Gotham Green Partners. Management believes this is the largest investment to date by a single investor in a publicly traded U.S. cannabis operating company. iAnthus plans to allocate the proceeds of this financing to repay a $20 million one-year note and accrued interest to VCP Bridge LLC; continue to build out cultivation facilities and dispensaries in the New York and Florida markets; and, potentially, to expand activities. The remaining expenditures for completing iAnthus’ Massachusetts and Vermont operations will be funded with current cash on hand, management assured.
- [By Spencer Israel]
The charts below are courtesy of VantagePoint, a platform that uses Artificial Intelligence and machine learning to forecast future price movements 1-3 days in advance with up to 86 percent accuracy. The blue line represents a predictive moving average that shows what’s going to happen three days in advance, and the black line is a simple 10-day moving average. A crossover of the blue line over the black line indicates a bullish signal from the software, and vice versa for a bearish signal.
iAthus Capital Holdings, Inc. (OTC: ITHUF)Up 94 percent YTD
Top 5 Casino Stocks To Buy For 2019: New Mountain Finance Corporation(NMFC)
Advisors' Opinion:- [By Shane Hupp]
These are some of the news headlines that may have effected Accern Sentiment’s scoring:
Get New Mountain Finance alerts: New Mountain Finance (NMFC) Expected to Post Quarterly Sales of $50.86 Million (americanbankingnews.com) Zacks: Analysts Anticipate New Mountain Finance (NMFC) Will Post Earnings of $0.34 Per Share (americanbankingnews.com) New Mountain Finance (NMFC) Stock Rating Lowered by Zacks Investment Research (americanbankingnews.com) Is this stock is more Volatile? New Mountain Finance Corporation (NMFC) (stockquote.review) New Mountain Finance Corporation (NMFC): Stock Have a Latest Story: (mosttradedstocks.com)A number of equities analysts have recently weighed in on NMFC shares. Zacks Investment Research raised shares of New Mountain Finance from a “hold” rating to a “buy” rating and set a $15.00 price target on the stock in a research note on Wednesday, March 21st. TheStreet downgraded shares of New Mountain Finance from a “b” rating to a “c+” rating in a research note on Wednesday, April 11th. ValuEngine downgraded shares of New Mountain Finance from a “buy” rating to a “hold” rating in a research note on Monday, April 2nd. Finally, Keefe, Bruyette & Woods set a $15.00 price target on shares of New Mountain Finance and gave the stock a “hold” rating in a research note on Thursday, March 1st. One investment analyst has rated the stock with a sell rating and three have assigned a hold rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $15.00.
No comments:
Post a Comment